Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

IMMX vs NMTC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMMX Captures Overall Composite Edge (50.6 HOLD vs 45.5 HOLD), While NMTC Leads 4–1 on Growth & Valuation Pillars

IMMX Overall Winner 6-Pillar Tally: IMMX 1 – 4 NMTC (1 Tie) Matrix Metrics: IMMX 7 – 1 NMTC

As of Nov 20, 2026, Immix Biopharma, Inc. (IMMX) captures the overall head-to-head institutional edge over NeuroOne Medical Technologies Corporation (NMTC) on higher Unified Composite conviction (50.6/100 HOLD vs. 45.5/100 HOLD) after splitting the core matrix 7–1 (led by Profitability & Quality), while NMTC wins 4–1 across the 6-pillar growth and valuation breakdown. IMMX trades at $6.96 (N/M Forward P/E, 0.0% operating margin) versus NMTC at $0.65 (N/M Forward P/E, -63.4% operating margin).

  • Growth vs. Quality Trade-Off: IMMX earns the overall head-to-head edge with a stronger Unified Composite Score (50.6/100 HOLD vs. NMTC 45.5/100 HOLD) and 1.65β · 76% Vol risk profile, whereas NMTC leads top-line expansion (+16.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.7); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMMX vs NMTC
IMMX NASDAQ Head-to-Head Winner
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$6.96
-1.14% 1D
Market Cap $590.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.65β · 76% Vol
Unified Composite Score
50.6 / 100 HOLD
Tech 38.0 Fund 64.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.1%), weak momentum, RSI 36
RSI-14: 35.7 · SMA20: $7.77 · SMA50: $9.25
NMTC NASDAQ
NeuroOne Medical Technologies Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.65
-3.38% 1D
Market Cap $6.1M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.55β · 105% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 60.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.83 · SMA50: $1.03

6-Pillar Scorecard Institutional Category Breakdown (IMMX 1 – 4 NMTC)

Columns: Metric · IMMX · NMTC
1. Valuation Multiples NMTC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.3x
2. Growth & Scale NMTC
Revenue Growth (YoY) +0.0% +16.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $12M
Market Cap $590.0M $6.1M
3. Profitability & Quality IMMX
Gross Margin N/A 23.0%
Operating Margin 0.0% -63.4%
Net Profit Margin 0.0% -59.7%
Return on Equity (ROE) -27.0% -124.7%
4. Balance Sheet & Cash Flow NMTC
Cash Generation (TTM) -$45M -$7.6M
Cash Flow Margin N/A -60.7%
Net Cash / Leverage $319M Net Cash $2.6M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NMTC
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 164.9% (30th %ile) N/A (N/A)
Put/Call OI Skew 0.05x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMMX (7) vs NMTC (1)
Institutional Metric IMMX NMTC Criterion Row Edge
Market Capitalization
Scale
$590.0M $6.1M Larger Scale IMMX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +16.3% Higher Growth NMTC
Operating Margin (TTM)
Profitability
0.0% -63.4% Higher Margin IMMX
Net Profit Margin
Profitability
0.0% -59.7% Higher Margin IMMX
Return on Equity (ROE)
Capital Efficiency
-27.0% -124.7% Higher ROE IMMX
52-Week Range Position
Momentum
28% ($4–$15) 2% ($1–$5) Stronger Trend IMMX
Beta / 30D Volatility
Risk Regime
1.65β · 76% Vol 1.55β · 105% Vol Lower Realized Risk IMMX
Unified Institutional Score
Composite Signal
50.6 / 100 (HOLD) 45.5 / 100 (HOLD) Higher Composite IMMX
Trailing 12M Revenue (USD)
Operating Scale
N/A $12M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 23.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$45M ($319M Net Cash) -$7.6M ($2.6M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IMMX +16.81 pp
IMMX: -16.65% · NMTC: -33.46%
3M Horizon IMMX +20.67 pp
IMMX: -48.86% · NMTC: -69.53%
6M Horizon IMMX +61.6 pp
IMMX: -20.73% · NMTC: -82.33%
1Y Horizon IMMX +61.05 pp
IMMX: +64.54% · NMTC: +3.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMMX vs NMTC. Trailing 12-month operating profitability (IMMX 0.0% vs NMTC -63.4%) and valuation multiples (IMMX N/M vs NMTC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IMMX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-27.0% · N/M
NMTC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$12M
Gross Margin23.0%
Op. Margin-63.4%
ROE / Fwd P/E-124.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMMX BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 164.9%
IV Percentile 30th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact IMMX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NMTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMMX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $590.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NMTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IMMX vs NMTC Key Questions & Quantitative Answers

As of Nov 20, 2026, Immix Biopharma, Inc. (IMMX) captures the overall head-to-head institutional edge over NeuroOne Medical Technologies Corporation (NMTC) on higher Unified Composite conviction (50.6/100 HOLD vs. 45.5/100 HOLD) after splitting the core matrix 7–1 (led by Profitability & Quality), while NMTC wins 4–1 across the 6-pillar growth and valuation breakdown. IMMX trades at $6.96 (N/M Forward P/E, 0.0% operating margin) versus NMTC at $0.65 (N/M Forward P/E, -63.4% operating margin). Growth vs. Quality Trade-Off: IMMX earns the overall head-to-head edge with a stronger Unified Composite Score (50.6/100 HOLD vs. NMTC 45.5/100 HOLD) and 1.65β · 76% Vol risk profile, whereas NMTC leads top-line expansion (+16.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.7); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NMTC leads the Growth & Scale pillar: IMMX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NMTC at +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin). On trailing 12-month operating scale, IMMX generates N/A in USD-normalized revenue versus $12M for NMTC. In operating R&D and SG&A reinvestment, IMMX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NMTC.

NMTC screens cheaper on headline valuation multiples. IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMMX (-27.0% ROE) versus NMTC (-124.7% ROE) capital efficiency.

In options market volatility and institutional positioning, IMMX carries 164.9% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.65β · 76% Vol realized risk). By comparison, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.